Ascendis Pharma A
corporate_fare Company Profile
Ascendis Pharma A (NASDAQ:ASND) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for ASND at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-14, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ASND spans 6-K, 4.
Recent high-impact activity:
- Ascendis Regains Obesity Drug Rights, Launches $400M Buyback
- Ascendis Pharma Board Authorizes $400M Share Repurchase Program
- Ascendis Pharma's TransCon CNP Shows Significant Benefits in Infants with Achondroplasia, Preventing Surgeries
- Ascendis Reports Positive Week 52 Infant Data for TransCon CNP in Achondroplasia
- Ascendis Settles YUVIWEL Litigation with BioMarin — 20% U.S. Royalty Through 2030
Financial Snapshot
Short Interest & Short Volume
4.90 days to coverFINRA reported short interest of 3,961,960 shares in ASND as of the September 15, 2026 settlement, a 5.7% decrease from the prior period — about 4.9 days to cover at its recent average daily volume. On October 7, 2026, 50.6% of ASND volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ASND, detected from its recent SEC filings · based on capital-structure filings through 2026-04-21.
Redemption of Convertible Notes · Triggered by Strong Stock Performance
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
ASND files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.